Login
Companies $NBIX
$165.31 +$0.00 (0.0%) After hours
NEUROCRINE BIOSCIENCES INC logo

NEUROCRINE BIOSCIENCES INC

neurocrine.com

What Do They Do?

Sells prescription medicines for tardive dyskinesia, Huntington’s chorea and congenital adrenal hyperplasia through specialty pharmacies and distributors, and develops treatments for neurological, psychiatric, endocrine and immunological disorders.

How Do They Make Money?

Product sales come from medicines sold through specialty pharmacies and distributors, with sales counted when customers obtain the products; collaboration revenue mainly comes from royalties on AbbVie and Tanabe sales.

revenue
SegmentShareRevenue
Net product sales
Sold outright

99%
FY2022: 97%
Collaboration revenues
Licensed
0.9%
FY2022: 3.2%

Who Are Their Customers?

INGREZZA is sold through select specialty pharmacy providers, wholesale distributors and specialty distributors; CRENESSITY is sold through a single specialty pharmacy provider.

Do Revenues Turn Into Profits?

Yes. It kept 17 cents of every revenue dollar as net income in FY2025 and turned 26 cents into free cash flow.

Operating income, FY2025
22% of revenue
▲ +9% vs FY2024 ($570.5M, 24%)
Net income, FY2025
17% of revenue
▲ +40% vs FY2024 ($341.3M, 14%)
Free cash flow, FY2025
26% of revenue
▲ +34% vs FY2024 ($557.2M, 24%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +41%
vs $794.9M in Q3 FY2025
Net income
▼ −1%
vs $209.5M in Q3 FY2025
Net product sales share of revenue vs 99.4% in Q3 FY2025
  • Jul 30, 2026 Raised INGREZZA sales guidance For full-year 2026, guidance rose from $2.7 billion to $2.8 billion up to $2.825 billion to $2.875 billion.
  • May 18, 2026 Completed the acquisition of Soleno Therapeutics Soleno became a wholly owned subsidiary, adding VYKAT XR, a treatment for hyperphagia in Prader-Willi syndrome.

Growing. Revenue grew 2.5x in 4 years, from $1.1B in FY2021 to $2.9B in FY2025, about 26% a year.

Additional treatment uses Valbenazine has expanded from a tardive dyskinesia treatment in the older report to also treat Huntington’s chorea; the latest report also describes crinecerfont as a launched treatment for congenital adrenal hyperplasia.

Revenue over time
Net product sales Collaboration revenues
$5B$2.5B$0

Who Do They Compete With?

Competes with Teva Pharmaceuticals Industries

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support